ESG Report 2024

Content 02 About this Report 2 . 1 Scope of the Report 2 . 2 Reporting Framework 2 . 3 Reporting Principles 2 . 4 Information and Feedback 03 About Us 3 . 1 3 . 2 About The United Laboratories Chairman Statement Safeguarding Life and Health 06 Normalising Healthiness 04 Governance ESG & Sustainability Board Statement 4 . 1 4 . 2 System ESG & Sustainability Governance Communication with Stakeholders 4 . 3 4 . 4 Materiality Assessment 1 . 1 Annual Performance 1 . 2 Annual Rewards 01 Performance Highlights in 2024 5 . 1 Corporate Governance 5 . 2 Risk Management 5 . 3 Business Ethics 5 . 4 Information Security 5 . 5 Protection of Intellectual Property Rights 5 . 6 Medical Ethics Excellent Operational Management 05 Effective Governance 6 . 1 R&D Innovation and 6 . 2 Enhancing Medical Accessibility 6 . 3 Improving Medical Affordabiliity 6 . 4 Enhancing Healthcare Standards 6 5 . Focus on Rare Disease Building Quality Brands 7 . 1 Quality Management 7 . 2 Product Marketing and Promotion 7 . 3 Customer Service 7 . 4 Pharmacovigilance 07 Pursuing Perfection Responsible Supply Chain Management 8 . 1 Sustainable Supply Chain Management 8 . 2 Management Supplier Risk Assessment and 8 . 3 Supplier Training 8 . 4 Green Supply Chain 08 Source Tracing 24 27 29 31 34 38 41 43 45 48 52 53 32 03 03 03 03 07 07 09 02 01 12 14 14 18 21 05 04 06 22